COVID-19 and neuromuscular disorders.
Identifieur interne : 001987 ( Main/Corpus ); précédent : 001986; suivant : 001988COVID-19 and neuromuscular disorders.
Auteurs : Amanda C. Guidon ; Anthony A. AmatoSource :
- Neurology [ 1526-632X ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Chloroquine (adverse effects), Coronavirus Infections (complications), Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Delivery of Health Care (MeSH), Deprescriptions (MeSH), Disease Progression (MeSH), Drug Development (MeSH), Enzyme Inhibitors (adverse effects), Guillain-Barre Syndrome (etiology), House Calls (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Immunologic Factors (adverse effects), Immunologic Factors (therapeutic use), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Infusions, Subcutaneous (MeSH), Macrolides (adverse effects), Muscular Diseases (etiology), Myasthenia Gravis (chemically induced), Neurology (education), Neuromuscular Diseases (complications), Neuromuscular Diseases (therapy), Pandemics (prevention & control), Pneumonia, Viral (complications), Pneumonia, Viral (prevention & control), Pneumonia, Viral (therapy), Practice Guidelines as Topic (MeSH), Research (MeSH), Risk Reduction Behavior (MeSH), Self Administration (MeSH), Telemedicine (MeSH), Viral Vaccines (therapeutic use).
- MESH :
- chemical , adverse effects : Antiviral Agents, Chloroquine, Enzyme Inhibitors, Hydroxychloroquine, Immunologic Factors, Immunosuppressive Agents, Macrolides.
- chemically induced : Myasthenia Gravis.
- complications : Coronavirus Infections, Neuromuscular Diseases, Pneumonia, Viral.
- education : Neurology.
- etiology : Guillain-Barre Syndrome, Muscular Diseases.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- chemical , therapeutic use : Immunologic Factors, Immunosuppressive Agents, Viral Vaccines.
- therapy : Coronavirus Infections, Neuromuscular Diseases, Pneumonia, Viral.
- COVID-19, COVID-19 Vaccines, Delivery of Health Care, Deprescriptions, Disease Progression, Drug Development, House Calls, Humans, Infusions, Subcutaneous, Practice Guidelines as Topic, Research, Risk Reduction Behavior, Self Administration, Telemedicine.
Abstract
The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.
DOI: 10.1212/WNL.0000000000009566
PubMed: 32284362
Links to Exploration step
pubmed:32284362Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 and neuromuscular disorders.</title><author><name sortKey="Guidon, Amanda C" sort="Guidon, Amanda C" uniqKey="Guidon A" first="Amanda C" last="Guidon">Amanda C. Guidon</name><affiliation><nlm:affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Amato, Anthony A" sort="Amato, Anthony A" uniqKey="Amato A" first="Anthony A" last="Amato">Anthony A. Amato</name><affiliation><nlm:affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32284362</idno><idno type="pmid">32284362</idno><idno type="doi">10.1212/WNL.0000000000009566</idno><idno type="wicri:Area/Main/Corpus">001987</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001987</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 and neuromuscular disorders.</title><author><name sortKey="Guidon, Amanda C" sort="Guidon, Amanda C" uniqKey="Guidon A" first="Amanda C" last="Guidon">Amanda C. Guidon</name><affiliation><nlm:affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Amato, Anthony A" sort="Amato, Anthony A" uniqKey="Amato A" first="Anthony A" last="Amato">Anthony A. Amato</name><affiliation><nlm:affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Neurology</title><idno type="eISSN">1526-632X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>COVID-19 (MeSH)</term><term>COVID-19 Vaccines (MeSH)</term><term>Chloroquine (adverse effects)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (therapy)</term><term>Delivery of Health Care (MeSH)</term><term>Deprescriptions (MeSH)</term><term>Disease Progression (MeSH)</term><term>Drug Development (MeSH)</term><term>Enzyme Inhibitors (adverse effects)</term><term>Guillain-Barre Syndrome (etiology)</term><term>House Calls (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Immunologic Factors (adverse effects)</term><term>Immunologic Factors (therapeutic use)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Infusions, Subcutaneous (MeSH)</term><term>Macrolides (adverse effects)</term><term>Muscular Diseases (etiology)</term><term>Myasthenia Gravis (chemically induced)</term><term>Neurology (education)</term><term>Neuromuscular Diseases (complications)</term><term>Neuromuscular Diseases (therapy)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (therapy)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Research (MeSH)</term><term>Risk Reduction Behavior (MeSH)</term><term>Self Administration (MeSH)</term><term>Telemedicine (MeSH)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Chloroquine</term><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term><term>Immunologic Factors</term><term>Immunosuppressive Agents</term><term>Macrolides</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Myasthenia Gravis</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Neuromuscular Diseases</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="education" xml:lang="en"><term>Neurology</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Guillain-Barre Syndrome</term><term>Muscular Diseases</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunologic Factors</term><term>Immunosuppressive Agents</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Neuromuscular Diseases</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>COVID-19 Vaccines</term><term>Delivery of Health Care</term><term>Deprescriptions</term><term>Disease Progression</term><term>Drug Development</term><term>House Calls</term><term>Humans</term><term>Infusions, Subcutaneous</term><term>Practice Guidelines as Topic</term><term>Research</term><term>Risk Reduction Behavior</term><term>Self Administration</term><term>Telemedicine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32284362</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>22</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and neuromuscular disorders.</ArticleTitle><Pagination><MedlinePgn>959-969</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000009566</ELocationID><Abstract><AbstractText>The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.</AbstractText><CopyrightInformation>© 2020 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guidon</LastName><ForeName>Amanda C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amato</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>From the Division of Neuromuscular Medicine, Department of Neurology, Massachusetts General Hospital (A.C.G.), and Division of Neuromuscular Medicine, Department of Neurology, Brigham and Woman's Hospital (A.A.A.), Harvard Medical School, Boston, MA. aguidon@partners.org aamato@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069340" MajorTopicYN="N">Deprescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006792" MajorTopicYN="N">House Calls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055104" MajorTopicYN="N">Infusions, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="N">Muscular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="N">education</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32284362</ArticleId><ArticleId IdType="pii">WNL.0000000000009566</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009566</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001987 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001987 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32284362
|texte= COVID-19 and neuromuscular disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32284362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |